A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).

Stopped The study was terminated due to the termination of the clinical development program.

Conditions

• Non-Squamous Non-Small Cell Lung Cancer

Interventions

• DRUG: Placebo
• DRUG: Placebo
• DRUG: RG1507
• DRUG: RG1507
• DRUG: erlotinib [Tarceva]

Sponsor

Hoffmann-La Roche